Enrique Rodilla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8937840/publications.pdf

Version: 2024-02-01

90	3,417	279798 23	144013 57
papers	citations	h-index	g-index

122	122	122	4849
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis. JAMA - Journal of the American Medical Association, 2006, 295, 180.	7.4	1,353
2	Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. European Heart Journal, 2014, 35, 3122-3133.	2.2	249
3	May Measurement Month 2018: a pragmatic global screening campaign to raise awareness of blood pressure by the International Society of Hypertension. European Heart Journal, 2019, 40, 2006-2017.	2.2	193
4	May Measurement Month 2019. Hypertension, 2020, 76, 333-341.	2.7	157
5	Persistent lipid abnormalities in statinâ€treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study. Diabetic Medicine, 2011, 28, 1343-1351.	2.3	79
6	Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19. Journal of Clinical Medicine, 2020, 9, 3136.	2.4	72
7	Long-Term Impact of Systolic Blood Pressure and Glycemia on the Development of Microalbuminuria in Essential Hypertension. Hypertension, 2005, 45, 1125-1130.	2.7	59
8	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Journal of the American Heart Association, 2016, 5, .	3.7	53
9	Prognostic Value of Microalbuminuria During Antihypertensive Treatment in Essential Hypertension. Hypertension, 2014, 64, 1228-1234.	2.7	52
10	Relationship Between 24-Hour Ambulatory Central Systolic Blood Pressure and Left Ventricular Mass. Hypertension, 2017, 70, 1157-1164.	2.7	52
11	Impact of Arterial Stiffness on All-Cause Mortality in Patients Hospitalized With COVID-19 in Spain. Hypertension, 2021, 77, 856-867.	2.7	44
12	Role of adipokines in obesityâ€associated hypertension. Acta Physiologica, 2010, 200, 107-127.	3.8	41
13	Uso de espironolactona o doxazosina en pacientes con hipertensiÃ³n arterial refractaria. Revista Espanola De Cardiologia, 2009, 62, 158-166.	1.2	36
14	Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the <scp>REACH</scp> Registry. Clinical Cardiology, 2017, 40, 710-718.	1.8	33
15	MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open, 2018, 8, e021038.	1.9	33
16	Analysis of the efficacy of an internet-based self-administered intervention (â€œLiving Betterâ€) to promote healthy habits in a population with obesity and hypertension: An exploratory randomized controlled trial. International Journal of Medical Informatics, 2019, 124, 13-23.	3.3	31
17	Impact of a Web-Based Exercise and Nutritional Education Intervention in Patients Who Are Obese With Hypertension: Randomized Wait-List Controlled Trial. Journal of Medical Internet Research, 2020, 22, e14196.	4.3	29
18	Identification and characterization of a monoclonal antibody to the membrane fatty acid binding protein. Lipids and Lipid Metabolism, 1992, 1125, 13-20.	2.6	28

#	Article	IF	Citations
19	Documento de posicionamiento sobre la incorporaciÃ³n de la ecografÃa clÃnica en los servicios de Medicina Interna. Revista Clinica Espanola, 2018, 218, 192-198.	0.6	27
20	Sub-clinical vascular disease in type 2 diabetic subjects: Relationship with chronic complications of diabetes and the presence of cardiovascular disease risk factors. European Journal of Internal Medicine, 2008, 19, 255-260.	2.2	26
21	Determinants of urinary albumin excretion reduction in essential hypertension: a long-term follow-up study. Journal of Hypertension, 2006, 24, 2277-2284.	0.5	23
22	The Fixed-Dose Combination of Olmesartan/Amlodipine Was Superior in Central Aortic Blood Pressure Reduction Compared with Perindopril/Amlodipine: A Randomized, Double-Blind Trial in Patients with Hypertension. Advances in Therapy, 2013, 30, 1086-1099.	2.9	23
23	Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients. Medicina ClÃnica, 2009, 132, 1-6.	0.6	21
24	Effect of physical activity on pulse wave velocity in elderly subjects with normal glucose, prediabetes or Type 2 Diabetes. Scientific Reports, 2018, 8, 8045.	3.3	17
25	The membrane fatty acid-binding protein is not identical to mitochondrial glutamic oxaloacetic transaminase (mGOT). Molecular and Cellular Biochemistry, 1990, 98, 191-9.	3.1	16
26	An internet-based self-administered intervention for promoting healthy habits and weight loss in hypertensive people who are overweight or obese: a randomized controlled trial. BMC Cardiovascular Disorders, 2015, 15, 83.	1.7	16
27	Arterial Destiffening in Previously Untreated Mild Hypertensives After 1 Year of Routine Clinical Management. American Journal of Hypertension, 2017, 30, 510-517.	2.0	16
28	Blood glucose control and quality of health care in nonâ€insulinâ€treated patients with Typeâ€ƒ2 diabetes in Spain: a retrospective and crossâ€sectional observational study. Diabetic Medicine, 2011, 28, 731-740.	2.3	15
29	Impact of abdominal obesity and ambulatory blood pressure in the diagnosis of left ventricular hypertrophy in never treated hypertensives. Medicina ClÃnica, 2014, 142, 235-242.	0.6	15
30	Importancia del sÃndrome metabÃ³lico en el controlde la presiÃ³n arterial y de la dislipemia. Medicina ClÃnica, 2004, 123, 601-605.	0.6	15
31	Spironolactone and Doxazosin Treatment in Patients With Resistant Hypertension. Revista Espanola De Cardiologia (English Ed), 2009, 62, 158-166.	0.6	13
32	Relationship between increased arterial stiffness and other markers of target organ damage. Medicina ClÃnica, 2010, 134, 528-533.	0.6	13
33	Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment. Journal of Hypertension, 2013, 31, 1683-1691.	0.5	13
34	Twenty-Fourâ€“Hour Central (Aortic) Systolic Blood Pressure: Reference Values and Dipping Patterns in Untreated Individuals. Hypertension, 2022, 79, 251-260.	2.7	13
35	Body weight variation and control of cardiovascular risk factors in essential hypertension. Blood Pressure, 2009, 18, 247-254.	1.5	12
36	Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: A multicenter, randomized, double-blind study. Blood Pressure, 2014, 23, 181-188.	1.5	12

#	Article	IF	Citations
37	Fixedâ€Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. Journal of Clinical Hypertension, 2016, 18, 528-535.	2.0	12
38	Uso clÃnico de las estatinas y objetivos terapÃ©uticos en relaciÃ³n con el riesgo cardiovascular. Medicina ClÃnica, 2003, 121, 527-531.	0.6	11
39	Should we perform an echocardiogram in hypertensive patients classified as having low and medium risk?. International Journal of Cardiology, 2006, 106, 41-46.	1.7	10
40	RelaciÃ³n entre la presiÃ³n arterial central y perifÃ©rica con la masa ventricular izquierda en hipertensos. Revista Espanola De Cardiologia, 2012, 65, 1094-1100.	1.2	10
41	Rigidez arterial en sujetos normotensos e hipertensos: frecuencia en farmacias comunitarias. Medicina ClÃnica, 2017, 149, 469-476.	0.6	10
42	America's Cup yacht racing: Race analysis and physical characteristics of the athletes. Journal of Sports Sciences, 2009, 27, 915-923.	2.0	8
43	Pulse wave velocity and augmentation index are not independently associated with carotid atherosclerosis in patients with rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 2601-2606.	2.2	8
44	Prevalencia de aneurisma de aorta abdominal en pacientes con alto riesgo cardiovascular. Revista Clinica Espanola, 2018, 218, 461-467.	0.6	8
45	2021 Spanish Society of Hypertension position statement about telemedicine. Hipertension Y Riesgo Vascular, 2021, 38, 186-196.	0.6	8
46	Thigh and buttock exertional pain for the diagnosis of peripheral arterial disease. European Journal of Internal Medicine, 2009, 20, 429-434.	2.2	5
47	Relationship of Central and Peripheral Blood Pressure to Left Ventricular Mass in Hypertensive Patients. Revista Espanola De Cardiologia (English Ed), 2012, 65, 1094-1100.	0.6	5
48	Emotional eating as a mediator between anxiety and cholesterol in population with overweight and hypertension. Psychology, Health and Medicine, 2017, 22, 911-918.	2.4	5
49	Automatic or manual arterial path for the ankle-brachial differences pulse wave velocity. PLoS ONE, 2018, 13, e0206434.	2.5	5
50	May Measurement Month 2018: an analysis of blood pressure screening results from Spain. European Heart Journal Supplements, 2020, 22, H119-H121.	0.1	5
51	Velocidad de onda de pulso brazo-tobillo con un dispositivo propio. Revista Clinica Espanola, 2021, 221, 145-150.	0.6	5
52	RELATIONSHIP BETWEEN 24-HOUR AMBULATORY BRACHIAL VERSUS AORTIC SYSTOLIC BLOOD PRESSURE AND LEFT VENTRICULAR MASS. THE INTERNATIONAL 24 HOUR AORTIC BLOOD PRESSURE CONSORTIUM. Journal of Hypertension, 2018, 36, e29.	0.5	4
53	The Impact of a Web-Based Lifestyle Educational Program (â€˜Living Betterâ€™) Reintervention on Hypertensive Overweight or Obese Patients. Nutrients, 2022, 14, 2235.	4.1	4
54	OS 13-09 RELATIONSHIP BETWEEN 24 HOUR AMBULATORY CENTRAL BLOOD PRESSURE AND LEFT VENTRICULAR MASS â€“ A PROSPECTIVE MULTICENTER STUDY. Journal of Hypertension, 2016, 34, e210-e211.	0.5	3

#	Article	IF	Citations
55	May Measurement Month 2017: an analysis of blood pressure screening in Spainâ€"Europe. European Heart Journal Supplements, 2019, 21, D107-D110.	0.1	3
56	Assessment of Arterial Stiffness by Brachial Oscillometry in Community Pharmacies for Managing Hypertension (COPHARTEN). Artery Research, 2019, 25, 121-130.	0.6	3
57	Control de la dislipemia en grupos clÃnicos especiales: mujeres, ancianos, VIH, enfermedad renal crÃ³nica, pacientes con sÃndrome metabÃ³lico. Revista Espanola De Cardiologia Suplementos, 2011, 11, 36-41.	0.2	2
58	DIFFERENCES IN AORTIC AUGMENTATION PRESSURE BETWEEN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS MEASURED IN COMMUNITY PHARMACIES IN SPAIN. Journal of Hypertension, 2019, 37, e209-e210.	0.5	2
59	Blood pressure measurement and left ventricular mass: The difficult search for the best fit. Hipertension Y Riesgo Vascular, 2019, 36, 1-4.	0.6	2
60	4D.10. Journal of Hypertension, 2015, 33, e63.	0.5	1
61	Â¿Han influido el algoritmo de prescripciÃ³n de la AdministraciÃ³n y las guÃas de manejo de la dislipemia de la ACC/AHA 2013 en el manejo de la dislipemia? Proyecto MEJORA-LO CV. Revista Clínica Espanola, 2020, 220, 282-289.	0.6	1
62	Body weight variation and control of cardiovascular risk factors in essential hypertension. Blood Pressure, 2009, 18, 247-254.	1.5	1
63	Oxidative stress and left ventricular mass and shape in essential hypertension. American Journal of Hypertension, 2005, 18, A122-A122.	2.0	0
64	Eficacia de una estrategia basada en ARA-II en el tratamiento de pacientes hipertensos con sÃndrome metabÃ³lico. Hipertension, 2008, 25, 141-146.	0.0	0
65	Respuesta. Revista Espanola De Cardiologia, 2009, 62, 712.	1.2	0
66	Additional Information Regarding the SEVITENSION Study. Advances in Therapy, 2014, 31, 777-779.	2.9	0
67	SAT0163â€...Stratification of Cardiovascular Risk by Carotid Ultrasound in Patients with Rheumatoid Arthritis: Results of A Population from the EAST of Spain. Annals of the Rheumatic Diseases, 2014, 73, 649.2-649.	0.9	0
68	FRI0083â€...Arterial Stiffness in Patients with Rheumatoid Arthritis. Value for Cardiovascular Risk Stratification:. Annals of the Rheumatic Diseases, 2014, 73, 411.2-411.	0.9	0
69	FRI0091â€...Arterial Stiffness Increases Thorough Time in Patients with Rheumatoid Arthritis. Factors Related to the Change. Annals of the Rheumatic Diseases, 2015, 74, 452.3-453.	0.9	0
70	SAT0127â€...Patients with Rheumatoid Arthritis Show Significantly Worse Subclinical Vascular Damage than Healthy and Hypertensive People:. Annals of the Rheumatic Diseases, 2015, 74, 696.3-696.	0.9	0
71	AB0373â€...Arterial Stiffness Increases Over Time in Patients with Rheumatoid Arthritis. Related Factors. Annals of the Rheumatic Diseases, 2015, 74, 1018.2-1018.	0.9	0
72	AB0372â€...Physical Exercise has no Influence on Markers of Subclinical Cardiovascular Disease in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2015, 74, 1018.1-1018.	0.9	0

#	Article	IF	Citations
73	PP.24.20. Journal of Hypertension, 2015, 33, e350.	0.5	0
74	PP.05.17. Journal of Hypertension, 2015, 33, e173.	0.5	0
75	Central blood pressure and vascular damage. Medicina ClÃnica (English Edition), 2015, 145, 49-54.	0.2	0
76	SAT0238â€…Subclinical Atherosclerosis Is Lower in Patients with Systemic Sclerosis than in Patients with Rheumatoid Arthritis:. Annals of the Rheumatic Diseases, 2016, 75, 754.3-755.	0.9	0
77	[PP.27.15] PREVALENCE OF HYPERTENSION DETERMINED IN COMMUNAL PHARMACIES OF THE VALENCIAN COMMUNITY (RIVALFAR-STUDY). Journal of Hypertension, 2016, 34, e290.	0.5	0
78	[PP.37.17] PREVALENCE OF VARIABLES ASSOCIATED WITH ARTERIAL STIFFNESS IN COMMUNAL PHARMACIES OF THE VALENCIAN COMMUNITY (RIVALFAR-STUDY). Journal of Hypertension, 2016, 34, e346.	0.5	0
79	HEMODYNAMIC MODULATORS (VOLEMIA, INOTROPY, CHRONOTROPY AND VASOACTIVITY) AND HEMODYNAMIC STATUS IN TREATMENT-NAÃVE, DEBUTING HYPERTENSIVE PATIENTS. Journal of Hypertension, 2018, 36, e56-e57.	0.5	0
80	MANAGEMENT OF HYPERTENSION ACCORDING TO HEMODYNAMIC MODULATORS BY IMPEDANCE CARDIOGRAPHY IS NOT SUPERIOR TO STANDARD CLINICAL CARE IN TREATING NAÃVE HYPERTENSIVE PATIENTS. Journal of Hypertension, 2018, 36, e162.	0.5	0
81	SUPPLEMENTATION OF VITAMIN D IN HYPERTENSIVE PATIENTS WITH CKD STAGE 3 AND VITAMIN D-DEFICIENCY DOES NOT IMPROVE ARTERIAL STIFFNESS. Journal of Hypertension, 2018, 36, e197.	0.5	0
82	DETERMINANTS OF INTIMA-MEDIA THICKNESS IN INCIDENT HYPERTENSION. Journal of Hypertension, 2019, 37, e208.	0.5	0
83	RESULTS OF MMM18 IN A SUBPOPULATION OF STUDENTS IN SPAIN. Journal of Hypertension, 2019, 37, e229.	0.5	0
84	Clinical ultrasonography in cardiovascular risk. Revista Clínica Espanõla, 2020, 220, 364-373.	0.5	0
85	Brachial-ankle pulse wave velocity with a custom device. Revista Clínica Espanõla, 2021, 221, 145-150.	0.5	0
86	IMPACT OF METABOLIC SYNDROME IN THE CONTROL OF BLOOD PRESSURE AND DISLIPIDAEMIA IN HYPERTENSIVE PATIENTS. Journal of Hypertension, 2004, 22, S85.	0.5	0
87	METABOLIC SYNDROME AND MICROALBUMINURIA IN NON TREATED HYPERTENSIVE PATIENTS. Journal of Hypertension, 2004, 22, S102.	0.5	0
88	CHANGES IN LEFT VENTRICULAR MASS IN HYPERTENSIVE PATIENTS. PROSPECTIVE STUDY. Journal of Hypertension, 2004, 22, S237.	0.5	0
89	The membrane fatty acid-binding protein is not identical to mitochondrial glutamic oxaloacetic transaminase (mGOT). , 1990, , 191-199.		0
90	EcografÃa clÃnica en el riesgo cardiovascular. Revista Clinica Espanola, 2020, 220, 364-373.	0.6	0